January 25, 2019 Drug Utilization Review Board
»
1. Call to order
1. Call to order
»
2. Approval of minutes from October 26, 2018 (vote required)
2. Approval of minutes from October 26, 2018 (vote required)
»
3. New business » - a. Acne agents, oral b. Acne agents, topical c. Analgesics, narcotic long d. Analgesics, narcotic short e. Angiotensin modulator combinations f. Angiotensin modulators g. Antimigraine agents, other h. Antimigraine agents, triptans i. Bladder relaxant preparations j. H. pylori treatment k. Immunomodulators, atopic dermatitis l. Intranasal rhinitis agents m. Movement disorders n. Neuropathic pain o. Phosphate binders p. Platelet aggregation inhibitors q. Progestins for cachexia r. Proton pump inhibitors s. Smoking cessation t. Stimulants and related agents a. Ryclora / Antihistamines, first generation b. Vanalice Gel / Antiparasitics, topical c. Xofluza / Antivirals, oral d. Kapspargo / Beta-blockers e. Nivestym / Colony stimulating factors f. Ilumya Syringe / Cytokine and CAM antagonists g. Takhzyro / HAE treatments h. Panzyga / Immune globulins
3. New business »
a. Acne agents, oral b. Acne agents, topical
c. Analgesics, narcotic long
d. Analgesics, narcotic short
e. Angiotensin modulator combinations
f. Angiotensin modulators
g. Antimigraine agents, other
h. Antimigraine agents, triptans
i. Bladder relaxant preparations
j. H. pylori treatment
k. Immunomodulators, atopic dermatitis
l. Intranasal rhinitis agents
m. Movement disorders
n. Neuropathic pain
o. Phosphate binders
p. Platelet aggregation inhibitors
q. Progestins for cachexia
r. Proton pump inhibitors
s. Smoking cessation
t. Stimulants and related agents
a. Ryclora / Antihistamines, first generation
b. Vanalice Gel / Antiparasitics, topical
c. Xofluza / Antivirals, oral
d. Kapspargo / Beta-blockers
e. Nivestym / Colony stimulating factors
f. Ilumya Syringe / Cytokine and CAM antagonists
g. Takhzyro / HAE treatments
h. Panzyga / Immune globulins
»
4. Therapeutic and clinical drug reviews and updates: Matt Lennertz, Pharm. D., Magellan Medicaid Administration
4. Therapeutic and clinical drug reviews and updates: Matt Lennertz, Pharm. D., Magellan Medicaid Administration
»
5. Executive work session
5. Executive work session
»
6. Announcements of drugs recommended for the Medicaid PDL (vote required)
6. Announcements of drugs recommended for the Medicaid PDL (vote required)
»
7. Retrospective DUR: Larry Dent, Pharm. D., BCPS, Conduent, LLC » - a. Report on recent retrospective DUR interventions: i. Opioid prescribing ii. Second generation antipsychotics in youth b. Report on recent retrospective DUR intervention outcomes: i. Attention deficit disorder/hyperactivity disorder (ADHD) high dose ii. Psychotropic drugs in adults iii. Migraine prevention and treatment c. Retrospective DUR proposals (vote required) i. Appropriate use of antibiotics ii. Medication adherence iii. Respiratory disease management
7. Retrospective DUR: Larry Dent, Pharm. D., BCPS, Conduent, LLC »
a. Report on recent retrospective DUR interventions: i. Opioid prescribing
ii. Second generation antipsychotics in youth
b. Report on recent retrospective DUR intervention outcomes:
i. Attention deficit disorder/hyperactivity disorder (ADHD) high dose
ii. Psychotropic drugs in adults
iii. Migraine prevention and treatment
c. Retrospective DUR proposals (vote required)
i. Appropriate use of antibiotics
ii. Medication adherence
iii. Respiratory disease management
»
8. Prospective prior authorization proposals (clinical edits): Christina Faulkner, Pharm. D., Health Information Designs, LLC (vote required ) » - a. Cytokine and CAM antagonists - addition of Olumiant criteria b. Epidiolex - new criteria c. Orilissa - new criteria
8. Prospective prior authorization proposals (clinical edits): Christina Faulkner, Pharm. D., Health Information Designs, LLC (vote required ) »
a. Cytokine and CAM antagonists - addition of Olumiant criteria b. Epidiolex - new criteria
c. Orilissa - new criteria
»
Items 9 & 10 » - 9. Retrospective drug use, criteria for outpatient use in Vendor Drug Program: Jennifer Seltzer, Pharm. D., University of Texas at Austin College of Pharmacy (vote required) a. 5-HT3 receptor antagonists b. Angiotensin II receptor blockers c. Angiotensin-converting enzyme inhibitors d. ADHD medications e. GLP-1 receptor agonists f. Oral antidiabetic agents g. Pramlintide h. Serotonin 5-HT1B/1D receptor agonists i. Substance P / Neurokinin 1 receptor antagonists 10. Adjourn
Items 9 & 10 »
9. Retrospective drug use, criteria for outpatient use in Vendor Drug Program: Jennifer Seltzer, Pharm. D., University of Texas at Austin College of Pharmacy (vote required) a. 5-HT3 receptor antagonists
b. Angiotensin II receptor blockers
c. Angiotensin-converting enzyme inhibitors
d. ADHD medications
e. GLP-1 receptor agonists
f. Oral antidiabetic agents
g. Pramlintide
h. Serotonin 5-HT1B/1D receptor agonists
i. Substance P / Neurokinin 1 receptor antagonists
10. Adjourn
